StockWatch
·

Jeena Sikho Lifecare Ltd Q2 FY27 Results

JSLLQ2 FY27 Results
Filing
Result:Weak· Market: Crashed#Margin squeeze#Cost led
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue235.134.8%23.9%
Total Income233.192.3%21.9%
Expenditure183.6721.5%63.2%
PBT49.5343.4%37.1%
Net Profit36.6344.4%37.7%
OPM30.62%10.41pp17.85pp
NPM15.71%11.89pp15.00pp
EPS2.9544.3%37.6%
View full financials

Adjusted PAT fell 37.7% YoY as cost growth (other expenses +114%, employees +45%) outran 23.9% revenue growth, compressing margins and segment profits in both Ayurvedic products and healthcare services — a clear below-par quarter on the sector's core profit-growth metric despite healthy topline.

Q2 FY-2027 RESULTS · JSLL

Jeena Sikho Q2 FY27: PAT falls 38% YoY on margin compression despite 24% revenue growth

PAT -37.66% YoY · revenue +23.85% · margins compressing

14 Nov 2026 · 3 min read
Revenue

₹235.13 Cr

+23.85% YoY

PAT (consolidated)

₹36.63 Cr

-37.66% YoY

Net margin

15.71%

-15pp YoY

EPS

₹2.95

Jeena Sikho Lifecare's Q2 FY27 (quarter ended September 30, 2026) was a weak quarter on profitability even as the topline kept growing: consolidated revenue rose 23.9% YoY to ₹235.13 Cr (₹189.85 Cr in Q2 FY26) and 4.8% QoQ (₹224.40 Cr in Q1 FY27), but consolidated PAT fell 37.7% YoY to ₹36.63 Cr (₹58.75 Cr a year ago) and 44.4% QoQ (₹65.89 Cr in Q1 FY27). Neither comparison period carries a material one-off, so the YoY decline is organic — cost growth outrunning revenue, not an exceptional item. Standalone PAT (₹36.34 Cr, EPS ₹2.92) tracks within a few lakh of consolidated (₹36.63 Cr group-level, EPS ₹2.95), so there's no standalone-vs-consolidated divergence to flag; consolidated is the primary read. Coverage is thin — JSLL has only one tracked analyst and no Q2 FY27 estimate or preview could be found, so the print can't be benchmarked against street consensus this quarter.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹235.13 Cr+4.8%+23.9%
Expenses₹183.67 Cr+21.5%+63.2%
PAT₹36.63 Cr-44.41%-37.66%
Net margin15.71%-11.9pp-15pp
EPS₹2.95-44.3%-37.6%

The margin bridge is the real story. Consolidated net profit margin nearly halved to 15.6% from 30.7% YoY (27.6% in Q1 FY27), and EBITDA margin (PBT plus depreciation and finance cost) fell to roughly 29.8% from 48.5% YoY and 41.0% QoQ. The single largest driver is the 'other expenses' line, up 114% YoY to ₹86.90 Cr (₹40.53 Cr in Q2 FY26) and 39% QoQ, consistent with the pace of clinic and hospital network build-out. Employee benefits expense rose 45.5% YoY to ₹48.27 Cr and depreciation & amortisation rose 58% YoY to ₹16.43 Cr, both tracking headcount and right-of-use-asset growth ahead of revenue catching up. The squeeze hit both operating segments: Ayurvedic products revenue grew 50% YoY to ₹143.89 Cr but segment profit still fell 16.2% YoY to ₹33.44 Cr, while Ayurvedic healthcare services revenue declined 4.4% YoY to ₹89.83 Cr with segment profit down 35.5% YoY to ₹29.61 Cr. Other income also swung unfavourably — from +₹14.02 Cr in Q1 FY27 (standalone) to -₹2.31 Cr this quarter — a reversal note 4 links to the Derabassi hospital land-and-building sale-and-leaseback completed this half; its exact quarter split isn't disclosed, but its absence this quarter removes a tailwind that had flattered Q1.

₹
296.27363.51430.75497.99565.23342.108-1109-0209-2510-2111-1211-13
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹342.1, down 11.1% over the past month of trading.

₹ Cr
024.8649.7374.5951.27Q1 FY26rev ₹174 Cr58.75Q2 FY26rev ₹190 Cr66.6Q3 FY26rev ₹222 Cr45.08Q4 FY26rev ₹216 Cr65.89Q1 FY27rev ₹224 Cr36.63Q2 FY27rev ₹235 Cr
Quarterly consolidated PAT, ₹ Crore
What management guided (1 FY-2027 call)
INR 3,000 crore revenue within 3 years, INR 1,000 crore PAT target. Maintain 30% YoY growth, 27-30% NPM, 40%+ EBITDA margin. Expand to 3,000-3,500 beds in FY27, 7,000-10,000 beds in 3-5 years.

— This quarter: missed

Against management's own August 2026 concall guidance — 30% YoY revenue growth, 27-30% NPM, 40%+ EBITDA margin, and a path to ₹3,000 Cr revenue and ₹1,000 Cr PAT within three years — this quarter missed on every margin metric (NPM 15.6%, EBITDA margin ~29.8%) and came in just under the growth bar (23.9% vs 30% YoY), at odds with the confident, cautiously-optimistic tone management struck last call. No standalone press release accompanied this filing beyond the board-outcome letter, so there's no fresh management commentary to reconcile against the print. Corporate activity continued regardless: Raipur hospital received NABH accreditation (October 1, 2026), the company launched 10 new Ayurvedic products (November 11, 2026) and incorporated Ayugenomics Private Limited as a 60%-owned subsidiary (November 11, 2026) for genomics, diagnostics and clinical research — expansion-era moves consistent with the cost growth visible in this quarter's P&L.

  • W1

    Whether revenue growth re-accelerates toward management's 30% YoY guidance bar (23.9% YoY this quarter).

  • W2

    Whether EBITDA margin recovers toward the 40%+ target (~29.8% this quarter vs 48.5% a year ago) as the cost base (other expenses +114% YoY) stabilises relative to revenue.

  • W3

    Progress on the FY27 bed-capacity target of 3,000-3,500 beds flagged on the prior concall, not disclosed in this filing.

Informational and educational content only. Not investment advice.